SCHEDULE 13G/A: Lilly Endowment Inc. Maintains Significant Stake in Eli Lilly and Co., Holding 10.2% of Common Stock
Beneficial Ownership Report
Lilly Endowment Inc. has filed an amendment to its Schedule 13G, reaffirming its beneficial ownership of 10.2% of Eli Lilly and Co.'s common stock as of December 31, 2024.
Summary
- Lilly Endowment Inc. reported beneficial ownership of 96,891,978 shares of Eli Lilly and Co. common stock.
- This ownership represents 10.2% of the total class of common stock outstanding.
- The percentage is based on 949,315,694 shares of common stock outstanding as of October 25, 2024, as reported in Eli Lilly and Co.'s Form 10-Q for the period ended September 30, 2024.
- Lilly Endowment Inc. holds sole voting power and sole dispositive power over all 96,891,978 shares.
- This filing is an Amendment No. 15 to the Schedule 13G, indicating ongoing, long-term ownership by the endowment.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment. It is a routine regulatory filing.
Positives
- The continued significant ownership by Lilly Endowment Inc., a long-standing entity with historical ties to the company, suggests a stable and committed shareholder base.
- The endowment's status as a not-for-profit corporation and private foundation may imply a long-term, less volatile investment horizon compared to other institutional investors.
Industry Context
This filing is a routine disclosure of a significant passive ownership stake in a major pharmaceutical company. It does not provide insights into broader industry trends or competitive dynamics, but rather confirms the continued investment by a long-term holder in a leading healthcare firm.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant, stable institutional holder's stake in the company, which can contribute to market stability and confidence.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | Period ended for Eli Lilly and Co.'s Form 10-Q, which reported shares outstanding. |
| 2024-10-25 | Most recent date for which shares outstanding information (949,315,694 shares) was publicly available, as reported in the Issuer's Form 10-Q. |
| 2024-12-31 | Date of event which requires filing of this statement, reflecting the beneficial ownership. |
| 2025-01-27 | Date the Schedule 13G/A was signed by Lilly Endowment Inc. |
Keywords
Eli Lilly and Co., Lilly Endowment Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Pharmaceuticals, Healthcare, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.